A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

NCT03706040 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: Risankizumab

Sponsor

AbbVie